Skip to main content
. 2020 May 31;13(6):1251–1259. doi: 10.1111/cts.12812

Figure 1.

Figure 1

Study design. Three different EVR doses (1.5, 2.25, or 3 mg) were orally administered 4× in a 12‐hour cycle to healthy men. Blood and saliva samples were withdrawn before (day (D)1) and after (D3, D8, and D15) oral administration of EVR and subjected to further analysis. EVR, everolimus.